These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 17515697

  • 1. Persistence with once-daily versus twice-daily bupropion for the treatment of depression in a large managed-care population.
    Stang P, Suppapanaya N, Hogue SL, Park D, Rigney U.
    Am J Ther; 2007; 14(3):241-6. PubMed ID: 17515697
    [Abstract] [Full Text] [Related]

  • 2. Better patient persistence with once-daily bupropion compared with twice-daily bupropion.
    Stang P, Young S, Hogue S.
    Am J Ther; 2007; 14(1):20-4. PubMed ID: 17303971
    [Abstract] [Full Text] [Related]

  • 3. Once-daily bupropion associated with improved patient adherence compared with twice-daily bupropion in treatment of depression.
    McLaughlin T, Hogue SL, Stang PE.
    Am J Ther; 2007; 14(2):221-5. PubMed ID: 17414593
    [Abstract] [Full Text] [Related]

  • 4. An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey.
    Granger AL, Fehnel SE, Hogue SL, Bennett L, Edin HM.
    J Affect Disord; 2006 Feb; 90(2-3):217-21. PubMed ID: 16360216
    [Abstract] [Full Text] [Related]

  • 5. Bupropion extended-release for depressive disorders.
    Jefferson JW.
    Expert Rev Neurother; 2008 May; 8(5):715-22. PubMed ID: 18457528
    [Abstract] [Full Text] [Related]

  • 6. Bupropion sustained release: a therapeutic overview.
    Davidson JR, Connor KM.
    J Clin Psychiatry; 1998 May; 59 Suppl 4():25-31. PubMed ID: 9554318
    [Abstract] [Full Text] [Related]

  • 7. Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL.
    Modell JG, Rosenthal NE, Harriett AE, Krishen A, Asgharian A, Foster VJ, Metz A, Rockett CB, Wightman DS.
    Biol Psychiatry; 2005 Oct 15; 58(8):658-67. PubMed ID: 16271314
    [Abstract] [Full Text] [Related]

  • 8. Bupropion sustained release: side effect profile.
    Settle EC.
    J Clin Psychiatry; 1998 Oct 15; 59 Suppl 4():32-6. PubMed ID: 9554319
    [Abstract] [Full Text] [Related]

  • 9. Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression.
    Jamerson BD, Krishnan KR, Roberts J, Krishen A, Modell JG.
    Psychopharmacol Bull; 2003 Oct 15; 37(2):67-78. PubMed ID: 14566216
    [Abstract] [Full Text] [Related]

  • 10. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners.
    Moss EL, Simpson JS, Pelletier G, Forsyth P.
    Psychooncology; 2006 Mar 15; 15(3):259-67. PubMed ID: 16041840
    [Abstract] [Full Text] [Related]

  • 11. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
    Jefferson JW, Pradko JF, Muir KT.
    Clin Ther; 2005 Nov 15; 27(11):1685-95. PubMed ID: 16368442
    [Abstract] [Full Text] [Related]

  • 12. Factors contributing to compliance with osteoporosis medication.
    Kertes J, Dushenat M, Vesterman JL, Lemberger J, Bregman J, Friedman N.
    Isr Med Assoc J; 2008 Mar 15; 10(3):207-13. PubMed ID: 18494234
    [Abstract] [Full Text] [Related]

  • 13. Effect of medication burden on persistent use of lipid-lowering drugs among patients with hypertension.
    Robertson TA, Cooke CE, Wang J, Shaya FT, Lee HY.
    Am J Manag Care; 2008 Nov 15; 14(11):710-6. PubMed ID: 18999905
    [Abstract] [Full Text] [Related]

  • 14. Bupropion-SR in treatment of social phobia.
    Emmanuel NP, Brawman-Mintzer O, Morton WA, Book SW, Johnson MR, Lorberbaum JP, Ballenger JC, Lydiard RB.
    Depress Anxiety; 2000 Nov 15; 12(2):111-3. PubMed ID: 11091936
    [Abstract] [Full Text] [Related]

  • 15. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.
    Reimherr FW, Cunningham LA, Batey SR, Johnston JA, Ascher JA.
    Clin Ther; 1998 Nov 15; 20(3):505-16. PubMed ID: 9663366
    [Abstract] [Full Text] [Related]

  • 16. The impact of bupropion on psychomotor performance.
    Paul MA, Gray G, Kenny G, Lange M.
    Aviat Space Environ Med; 2002 Nov 15; 73(11):1094-9. PubMed ID: 12433233
    [Abstract] [Full Text] [Related]

  • 17. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population.
    Tournier M, Moride Y, Crott R, du Fort GG, Ducruet T.
    J Affect Disord; 2009 May 15; 115(1-2):160-6. PubMed ID: 18694602
    [Abstract] [Full Text] [Related]

  • 18. Varenicline and bupropion sustained-release combination therapy for smoking cessation.
    Ebbert JO, Croghan IT, Sood A, Schroeder DR, Hays JT, Hurt RD.
    Nicotine Tob Res; 2009 Mar 15; 11(3):234-9. PubMed ID: 19246427
    [Abstract] [Full Text] [Related]

  • 19. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
    Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, Henderson DC, Schoenfeld DA, Rigotti NA, Goff DC.
    J Clin Psychopharmacol; 2007 Aug 15; 27(4):380-6. PubMed ID: 17632223
    [Abstract] [Full Text] [Related]

  • 20. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX, Ye X, Lee KY, Dupclay L, Plauschinat C.
    Clin Ther; 2008 Aug 15; 30 Pt 2():2217-27. PubMed ID: 19281916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.